Eleven Biotherapeutics Appoints Barry Gertz, MD, PhD, And Jay S. Duker, MD, To Board Of Directors

Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the election of Barry Gertz, MD, PhD, and Jay S. Duker, MD, to the company’s Board of Directors. Each of these new Board members brings more than 25 years of experience that is relevant to Eleven’s progress in advancing its pipeline of innovative therapies for ocular diseases.

Help employers find you! Check out all the jobs and post your resume.